Mitch C. Hill - Mar 12, 2024 Form 4 Insider Report for Inari Medical, Inc. (NARI)

Role
Chief Financial Officer
Signature
/s/ Shannon Trevino, attorney-in-fact for Mitch C. Hill
Stock symbol
NARI
Transactions as of
Mar 12, 2024
Transactions value $
-$248,719
Form type
4
Date filed
3/14/2024, 04:31 PM
Previous filing
Feb 21, 2024
Next filing
Apr 3, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NARI Common Stock Options Exercise $2.74K +6K +3.27% $0.46* 189K Mar 12, 2024 Direct F1
transaction NARI Common Stock Sale -$251K -6K -3.17% $41.91 183K Mar 12, 2024 Direct F1, F2
transaction NARI Common Stock Sale -$43 -1 0% $42.58 183K Mar 12, 2024 Direct F1
holding NARI Common Stock 1.6K Mar 12, 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NARI Stock Options (Right to Buy) Options Exercise $0 -6K -6.35% $0.00 88.5K Mar 12, 2024 Common Stock 6K $0.46 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $41.41 to $42.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter.